Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study

Autor: Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, Shinsuke Otagiri, Kana Yamanashi, Kazunori Nagashima, Reizo Onishi, Keiji Yagisawa, Haruto Nishimura, Takahiro Ito, Atsuo Maemoto, Naoya Sakamoto

Publikováno v: Intestinal Research, Vol 20, Iss 1, Pp 78-89 (2022)

Background/Aims Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effec

Externí odkaz: https://doaj.org/article/eb1855429b2f4039ab318c07d09f3ffd

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Autor: Keiji Yagisawa, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Takahiko Toyonaga, Miki Miura, Mari Hayashida, Eiko Saito, Masaru Nakano, Hajime Matsubara, Tadakazu Hisamatsu, Toshifumi Hibi

Publikováno v: Intestinal Research, Vol 17, Iss 1, Pp 87-93 (2019)

Background/Aims Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabil

Externí odkaz: https://doaj.org/article/cd43095aa4ee43968684f86ec53bfd8d

Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

Autor: Shinji Okabayashi, Junichi Tanaka, Eiko Saito, Osamu Takeuchi, Takahiko Toyonaga, Taku Kobayashi, Keiji Yagisawa, Shintaro Sagami, Toshifumi Hibi, Masaru Nakano, Ryo Ozaki, Satoshi Kuronuma

Publikováno v: Intestinal Research

Background/aims The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, dependi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9380e3ab9810404df3068c95477bb88
http://europepmc.org/articles/PMC6505090

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Autor: Tadakazu Hisamatsu, Shinji Okabayashi, Hajime Matsubara, Ryo Ozaki, Toshifumi Hibi, Mari Hayashida, Eiko Saito, Takahiko Toyonaga, Taku Kobayashi, Keiji Yagisawa, Masaru Nakano, Miki Miura

Publikováno v: Intestinal Research
Intestinal Research, Vol 18, Iss 3, Pp 343-344 (2020)
Intestinal Research, Vol 17, Iss 1, Pp 87-93 (2019)

Background/aims Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991eb8c843dca40fdfcb158c47f1a506
https://pubmed.ncbi.nlm.nih.gov/30541227